Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients

Last updated: October 19, 2020
Sponsor: Gadjah Mada University
Overall Status: Active - Recruiting

Phase

2

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04594330
002/05/2020
  • Ages > 18
  • All Genders

Study Summary

Virgin Coconut Oil (VCO) contains multiple compounds which have antibacterial, antiviral, and immunomodulatory properties. The role of VCO as an antivirus to treat COVID-19 requires further studies. A previous study has investigated the used of 30 ml of VCO to healthy volunteers for a month and reported no side effect. Here the investigators conduct a pilot trial to investigate the effect of VCO towards the clinical outcomes of COVID-19 patients in Indonesia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients, age ≥ 18 years old.

  • COVID-19 patients diagnosed with nasopharyngeal/oropharyngeal PCR swab specimens thatare treated in Central Public Hospital Dr. Sardjito, Teaching Hospital of UniversitasGadjah Mada (UGM), and Yogyakarta COVID-19 referral hospitals.

  • Patients with mild and moderate pneumonia symptoms that are treated in Central PublicHospital Dr. Sardjito, Teaching Hospital of Universitas Gadjah Mada (UGM), andYogyakarta COVID-19 referral hospitals.

Exclusion

Exclusion Criteria:

  • Patients with liver function disorder.

  • VCO hypersensitivity.

  • Patients with severe pneumonia and/or Acute Respiratory Distress Syndrome (ARDS).

  • Pregnant patients.

  • Patients with malignant comorbidity.

  • Critical or unconscious patients.

  • Patients using other immunomodulators similar to VCO within less than three daysbefore VCO administration.

Study Design

Total Participants: 60
Study Start date:
June 01, 2020
Estimated Completion Date:
December 31, 2020

Study Description

The subjects of this pilot study are patients diagnosed with COVID-19 in Central Public Hospital Dr. Sardjito, Teaching Hospital of Universitas Gadjah Mada (UGM), and Yogyakarta COVID-19 referral hospitals (RSUD Wonosari and Sleman). The COVID-19 patients are recruited according to the inclusion and exclusion criteria, then divided randomly into two groups. Group I, the intervention group, consists of COVID-19 patients receiving standard therapy and 15 mL of VCO twice a day for 14 days. Group II, the control group, consists of COVID-19 patients receiving standard therapy and 15 mL of placebo twice a day for 14 days. Both groups are monitored for four weeks with a nasopharyngeal or oropharyngeal Polymerase Chain Reaction (PCR) swab test.

Connect with a study center

  • Central Public Hospital Dr. Sardjito

    Yogyakarta,
    Indonesia

    Active - Recruiting

  • RSUD Wonosari

    Yogyakarta,
    Indonesia

    Active - Recruiting

  • RSUP Sleman

    Yogyakarta,
    Indonesia

    Active - Recruiting

  • Teaching Hospital of Universitas Gadjah Mada (UGM)

    Yogyakarta,
    Indonesia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.